Edwards Lifesciences Corp

Edwards Lifesciences insider RSU purchase signals confidence in TAVR tech; robust clinical data, EU clearance, and safety profile highlight growth and patient impact.

CEO buys 25,350 Edwards Lifesciences shares at $59.26, signaling confidence while market sees modest decline – what it means for investors and valuation.

Edwards Lifesciences insider buy by executive Daniel Lippis signals strong confidence ahead of the JenaValve acquisition, hinting at potential upside for investors.